raise $100 million to $150 million, said John Oyler, its chief executive officer. BeiGene is part of a vanguard of health-care startups in the world���s most populous country. They are tapping government incentives that promote research and innovation,...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to China���s Cancer Deaths Spur Merck Investment in Beijing Biotech
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account